Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
22 pending office actions • 16 art units • 19 examiners • 0 of 22 (0%) have an AI response strategy ready • 22 patents granted in the last 365 days
Lonza Ltd. has 21 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions span 15 distinct art units. The company works with 18 distinct examiners, which means that most of the 21 pending office actions are being reviewed by different individuals at the patent office. This high number of art units relative to the actions indicates a very broad technical portfolio.
TRAN, CHRISTINA L is the busiest examiner, managing 3 pending office actions. The remaining actions are distributed among other examiners. This distribution, where 18 distinct examiners handle 21 pending office actions, results in limited examiner overlap. With 15 distinct art units involved, practitioners must address the technical requirements of the 15 distinct art units. The portfolio involves 18 distinct examiners, requiring the company to manage these individual relationships simultaneously. Maintaining a cohesive strategy across 15 different specialized groups will be a key challenge for the prosecution team.
Based on the USPTO statutory response window for each pending office action. 8 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 8 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (9%) |
| §103 only | 9 (41%) |
| §112 only | 1 (5%) |
| Double-patenting + other | 8 (36%) |
| Multi-statute (no §101) | 2 (9%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TRAN, CHRISTINA L | 3 | 51.6% | +48.2% |
| MCCORMICK, CATHERINE LYNN | 2 | 50.0% | +42.5% |
| WESTON, ALYSSA G | 1 | 59.8% | +50.9% |
| VANHORN, ABIGAIL LOUISE | 1 | 46.8% | +22.4% |
| PAK, YONG D | 1 | 74.6% | +14.3% |
| MIANO, JOSEPH PAUL | 1 | 36.0% | +63.3% |
| MEAH, MOHAMMAD Y | 1 | 70.8% | +42.7% |
| LEVIN, JOEL D | 1 | 58.1% | +35.2% |
| COUNTS, GARY W | 1 | 58.9% | +29.5% |
| KRISHNAN, GANAPATHY | 1 | 52.8% | +1.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17635298 | EXTRACELLULAR VESICLES WITH ANTISENSE OLIGONUCLEOTIDES TARGETING KRAS | ALLEN, SARAH ELIZABETH | 47d |
| 18780030 | METHODS OF CELL SELECTION AND MODIFYING CELL METABOLISM | PAK, YONG D | — |
| 18462800 | METHOD FOR PRODUCING BIOLOGIC PRODUCT VARIANTS | MIANO, JOSEPH PAUL | — |
| 17906177 | EXTRACELLULAR VESICLES FOR TREATING NEUROLOGICAL DISORDERS | LEE, JIA-HAI | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17635322 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING STAT6 | TRAN, CHRISTINA L | 7d |
| 17776932 | METHODS OF CELL SELECTION | LEVIN, JOEL D | 29d |
| 18938929 | QUALITY CONTROL METHODS FOR AUTOMATED CELL PROCESSING | WESTON, ALYSSA G | — |
| 18300994 | METHODS FOR NUCLEAR REPROGRAMMING USING SYNTHETIC TRANSCRIPTION FACTORS | MCCORMICK, CATHERINE LYNN | — |
| 18063982 | METHODS FOR PRODUCING IMMUNE CELL CULTURES | VANHORN, ABIGAIL LOUISE | — |
| 18780030 | METHODS OF CELL SELECTION AND MODIFYING CELL METABOLISM | PAK, YONG D | — |
| 18462800 | METHOD FOR PRODUCING BIOLOGIC PRODUCT VARIANTS | MIANO, JOSEPH PAUL | — |
| 18454930 | CARBON-SOURCE REGULATED PROTEIN PRODUCTION IN A RECOMBINANT HOST CELL | MEAH, MOHAMMAD Y | — |
| Art Unit | Apps |
|---|---|
| 1637 | 4 |
| 1638 | 2 |
| 1652 | 2 |
| 1636 | 1 |
| 1631 | 1 |
| 1633 | 1 |
| 1678 | 1 |
| 1693 | 1 |
| 1612 | 1 |
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18938929 | QUALITY CONTROL METHODS FOR AUTOMATED CELL PROCESSING | WESTON, ALYSSA G | — | §103§112DP | Non-Final OA | — | Pending | Nov 06, 2024 |
| 18300994 | METHODS FOR NUCLEAR REPROGRAMMING USING SYNTHETIC TRANSCRIPTION FACTORS | MCCORMICK, CATHERINE LYNN | 1638 | §103Other | Non-Final OA | — | Pending | Apr 14, 2023 |
| 18063982 | METHODS FOR PRODUCING IMMUNE CELL CULTURES | VANHORN, ABIGAIL LOUISE | 1636 | §103 | Non-Final OA | — | Pending | Dec 09, 2022 |
| 18780030 | METHODS OF CELL SELECTION AND MODIFYING CELL METABOLISM | PAK, YONG D | 1652 | §103§112 | Non-Final OA | — | Pending | Jul 22, 2024 |
| 18462800 | METHOD FOR PRODUCING BIOLOGIC PRODUCT VARIANTS | MIANO, JOSEPH PAUL | 1631 | §101§102§103 | Non-Final OA | — | Pending | Sep 07, 2023 |
| 18454930 | CARBON-SOURCE REGULATED PROTEIN PRODUCTION IN A RECOMBINANT HOST CELL | MEAH, MOHAMMAD Y | 1652 | §103§112DP | Non-Final OA | — | Pending | Aug 24, 2023 |
| 17776932 | METHODS OF CELL SELECTION | LEVIN, JOEL D | 1633 | §103 | Final Rejection | 29d | Pending | May 13, 2022 |
| 17735555 | COMPOSITIONS AND METHODS FOR THE DETECTION OF HOST CELL PROTEINS | COUNTS, GARY W | 1678 | §103 | Final Rejection | — | Pending | May 03, 2022 |
| 17434442 | Purification Process for Biological Molecules Such as Plasmid DNA Using Anionic Exchange Chromatography | KRISHNAN, GANAPATHY | 1693 | §103 | Non-Final OA | — | Pending | Aug 27, 2021 |
| 18546131 | EXTRACELLULAR VESICLE LINKED TO A BIOLOGICALLY ACTIVE MOLECULE VIA AN OPTIMIZED LINKER AND AN ANCHORING MOIETY | LEWOCZKO, EVAN MICHAEL | 1612 | §103DP | Non-Final OA | — | Pending | Aug 11, 2023 |
| 17906177 | EXTRACELLULAR VESICLES FOR TREATING NEUROLOGICAL DISORDERS | LEE, JIA-HAI | 1658 | §101§102§103DP | Non-Final OA | — | Pending | Aug 01, 2023 |
| 18246312 | PROCESS FOR PREPARING EXTRACELLULAR VESICLES | ROYCE, LIAM A | 1777 | §103 | Final Rejection | 7d | Pending | Mar 22, 2023 |
| 18246301 | PROCESS FOR PREPARING EXTRACELLULAR VESICLES | BREWSTER, HAYDEN R | 1779 | §103 | Final Rejection | 44d overdue | Pending | Mar 22, 2023 |
| 18057709 | COMPOSITIONS OF ENGINEERED EXOSOMES AND METHODS OF LOADING LUMINAL EXOSOMES PAY-LOADS | CARTER, SANDRA DILLAHUNT | 1674 | §112 | Non-Final OA | — | Pending | Nov 21, 2022 |
| 18050017 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING STAT6 | TRAN, CHRISTINA L | 1637 | §103DP | Non-Final OA | — | Pending | Oct 26, 2022 |
| 17757345 | AUTOMATED PRODUCTION OF VIRAL VECTORS | MCCORMICK, CATHERINE LYNN | 1638 | §103 | Final Rejection | — | Pending | Jun 14, 2022 |
| 17635315 | EXTRACELLULAR VESICLES WITH STAT3-ANTISENSE OLIGONUCLEOTIDES | TRAN, CHRISTINA L | 1637 | §103 | Final Rejection | — | Pending | Feb 14, 2022 |
| 17635322 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING STAT6 | TRAN, CHRISTINA L | 1637 | §103§112DP | Final Rejection | 7d | Pending | Feb 14, 2022 |
| 17635298 | EXTRACELLULAR VESICLES WITH ANTISENSE OLIGONUCLEOTIDES TARGETING KRAS | ALLEN, SARAH ELIZABETH | 1637 | §102§103§112 | Non-Final OA | 47d | Pending | Feb 14, 2022 |
| 17634897 | EXTRACELLULAR VESICLE LINKED TO MOLECULES AND USES THEREOF | MEJIAS, SAMANTHA LEE | 1618 | §103DP | Final Rejection | 3d overdue | Pending | Feb 11, 2022 |
| 17441162 | EXTRACELLULAR VESICLE CONJUGATES AND USES THEREOF | ANTHOPOLOS, PETER | 1611 | §103§112DP | Non-Final OA | 17d overdue | Pending | Sep 20, 2021 |
| 17293833 | ENGINEERED EXTRACELLULAR VESICLES AND USES THEREOF | ESPINOSA, CLAUDIA EDILMA | 1654 | §103§112DP | Final Rejection | 13d | Pending | May 13, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial